Psychedelic medicine biotech company developing psychedelic-inspired medicine and therapies to treat addiction and mental conditions MindMed Inc. (NASDAQ: MNMD) (NEO: MMED) announced having joined Clinical Trials Transformation Initiative (CTTI) where it will make contributions in developing and driving adoption of practices that enhance the quality and efficiency of clinical trials.
CTTI comprises of 80 member organizations who seek to advance higher quality clinical trials and speeding the path to new therapies and other medical products. CTTI meets with its members together with over 500 multi-stakeholder organizations and individuals from across the medical industry to discuss and exchange ideas and come to some agreement on mega challenges facing clinical trials.
MindMed is now a member of CTTI’s steering committee meaning that it will be mandated with making contributions towards setting projects priorities within the agenda of CTTI and also serving the on the teams which create resources and recommendations to transform clinical trials around the world.
“We welcome every meaningful opportunity to actively participate in the advancement of innovations that are ultimately contributing to the improvement of the way we develop medicine and bring treatment to the patient. MindMed and CTTI are both focused on improving clinical trials on behalf of patients and thus being a part of their mission aligns perfectly with the goals and values we have at MindMed. We look forward to being active partners in this initiative,” said MindMed’s chief medical officer, Daniel R. Karlin.